ANKRD22 and familial pancreatic carcinoma: A nine-gene signature (MET, KLK10, COL17A1, CEP55, ANKRD22, ITGB6, ARNTL2, MCOLN3 and SLC25A45) [68] and a four-gene signature (LYRM1, KNTC1, IGF2BP2 and CDC6) [69] were proposed to predict the overall survival of pancreatic cancer patients.